Prot #SMX 18-001: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2−Breast Cancer with an ESR1 Mutat

Project: Research project

Project Details

Effective start/end date5/28/205/28/23


  • Linical Americas (Prot #SMX 18-001)
  • Sermonix Pharmaceuticals, Inc. (Prot #SMX 18-001)